Antibody drug conjugate - Chiome Bioscience/Heidelberg Pharma
Latest Information Update: 19 Jul 2022
At a glance
- Originator Chiome Bioscience; Heidelberg Pharma AG
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Peptides
- Mechanism of Action RNA polymerase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer